Cargando…

US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales

BACKGROUND: Pivmecillinam is approved for the treatment of adults with uncomplicated urinary tract infection (uUTI) in Canada and Europe and is pending United States (US) Food and Drug Administration submission for consideration for approval. US-focused health care decision-analytics were developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lodise, Thomas P, Henriksen, Anne Santerre, Hadley, Thomas, Patel, Nimish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516593/ https://www.ncbi.nlm.nih.gov/pubmed/34660834 http://dx.doi.org/10.1093/ofid/ofab380

Ejemplares similares

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021)

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial
por: Vik, Ingvild, et al.
Publicado: (2018)

Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men
por: Montelin, Hanna, et al.
Publicado: (2019)

Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI)
por: Tverring, Jonas, et al.
Publicado: (2023)

Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus—Cumulative Observational Data from Four Recent Clinical Studies
por: Jansåker, Filip, et al.
Publicado: (2019)

Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs Among Adult Patients With Complicated Urinary Tract Infections
por: Lodise, Thomas P, et al.
Publicado: (2022)

Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial()
por: Jansåker, Filip, et al.
Publicado: (2019)

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019
por: Hawser, Stephen, et al.
Publicado: (2021)

An Assessment of Inappropriate Antibiotic Use and Guideline Adherence for Uncomplicated Urinary Tract Infections
por: Durkin, Michael J, et al.
Publicado: (2018)

1617. Mecillinam susceptibility against Enterobacterales isolated from urinary tract infections from US patients in 2018
por: Hawser, Stephen, et al.
Publicado: (2020)

A Clinical Prediction Tool for Extended-Spectrum Cephalosporin Resistance in Community-Onset Enterobacterales Urinary Tract Infection
por: Weinstein, Erica J, et al.
Publicado: (2019)

Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase–Producing Enterobacterales Urinary Tract Infections
por: Anderson, Daniel T, et al.
Publicado: (2022)

Outpatient Antibiotic Prescribing Practices for Uncomplicated Urinary Tract Infection in Women in the United States, 2002–2011
por: Kobayashi, Miwako, et al.
Publicado: (2016)

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

Retracted: In vivo mecillinam resistance in Escherichia coli after pivmecillinam treatment of a urinary tract infection
Publicado: (2019)

Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females
por: Yetsko, Aidan, et al.
Publicado: (2023)

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)
por: Henriksen, Anne Santerre, et al.
Publicado: (2021)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Multidrug Resistance of Escherichia coli From Outpatient Uncomplicated Urinary Tract Infections in a Large United States Integrated Healthcare Organization
por: Ku, Jennifer H, et al.
Publicado: (2023)

Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States
por: Lodise, Thomas P, et al.
Publicado: (2022)

Clinical Risk Scores to Predict Nonsusceptibility to Trimethoprim-Sulfamethoxazole, Fluoroquinolone, Nitrofurantoin, and Third-Generation Cephalosporin Among Adult Outpatient Episodes of Complicated Urinary Tract Infection
por: Lodise, Thomas P, et al.
Publicado: (2023)

Antibiotic treatment failure of uncomplicated urinary tract infections in primary care
por: Koh, Sky Wei Chee, et al.
Publicado: (2023)

Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study
por: Jansåker, Filip, et al.
Publicado: (2019)

Impact of the 2019 Food and Drug Administration Guidance for Uncomplicated Urinary Tract Infection on Treatment Response Rates: A Reanalysis of a Clinical Trial of Nitrofurantoin vs Fosfomycin
por: Grant, Rebecca, et al.
Publicado: (2023)

The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol
por: Jansåker, Filip, et al.
Publicado: (2016)

Uncomplicated urinary tract infections in Swedish primary care; etiology, resistance and treatment
por: Kornfält Isberg, Helena, et al.
Publicado: (2019)

The Niche for Escherichia coli Sequence Type 131 Among Veterans: Urinary Tract Abnormalities and Long-Term Care Facilities
por: Drekonja, Dimitri M., et al.
Publicado: (2016)

Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland
por: O’Kelly, Fardod, et al.
Publicado: (2016)

Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting
por: Derington, Catherine G, et al.
Publicado: (2020)

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)
por: Sader, Helio S, et al.
Publicado: (2023)

The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study
por: Hansen, Bjørn Åsheim, et al.
Publicado: (2022)

The impact of health care provider relationships and communication dynamics on urinary tract infection management and antibiotic utilization for long-term care facility residents treated in the emergency department: A qualitative study
por: Valmadrid, Luke Carmichael, et al.
Publicado: (2021)

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France
por: Farfour, Eric, et al.
Publicado: (2022)

Construction of a patient decision aid for the treatment of uncomplicated urinary tract infection in primary care
por: Vincent, Yves-Marie, et al.
Publicado: (2021)

Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV
por: Henderson, Heather I, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on the rates of central line–associated bloodstream infection and catheter-associated urinary tract infection in an intensive care setting: National experience
por: Alsaffar, Manar Jaffer, et al.
Publicado: (2023)

Risk Factors for and Mechanisms of COlistin Resistance Among Enterobacterales: Getting at the CORE of the Issue
por: Mills, John P, et al.
Publicado: (2021)

Psychosocial burden of recurrent uncomplicated urinary tract infections
por: Naber, Kurt G., et al.
Publicado: (2022)

Cost-effectiveness of different strategies for diagnosis of uncomplicated urinary tract infections in women presenting in primary care
por: Bosmans, Judith E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sf74do3sd63hic8gbh1su0nbht